Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 21 to 30 of 480 total matches.

Expanded Table: Some Vaccines Recommended for Use in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • May 07, 2018  (Issue 1546)
, Diphtheria (Td) Tetanus and Diptheria Toxoids Tenivac (SanofiPasteur) 0.5 mL IM 3 doses (0, 1, and 6 ...
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Med Lett Drugs Ther. 2018 May 7;60(1546):e82-85 | Show Introduction Hide Introduction

Siponimod (Mayzent) - A New Drug for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
– Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing ...
The FDA has approved siponimod (Mayzent – Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Siponimod is the second S1P receptor modulator to be approved in the US; fingolimod (Gilenya), which is approved for oral treatment of relapsing forms of MS in patients ≥10 years old, was the first. The purine antimetabolite cladribine (Mavenclad) was also recently...
Med Lett Drugs Ther. 2019 May 6;61(1571):70-2 | Show Introduction Hide Introduction

Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
that are chemically similar to endogenous hormones such as estradiol and progesterone.1 FDA-approved formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketing Bijuva as "the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule".
Med Lett Drugs Ther. 2019 Jul 1;61(1575):99-101 | Show Introduction Hide Introduction

Minocycline Foam (Zilxi) for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
Minocycline Foam (Zilxi) for Rosacea The FDA has approved a 1.5% topical foam formulation ...
The FDA has approved a 1.5% topical foam formulation of minocycline (Zilxi – Foamix) for treatment of inflammatory lesions of rosacea in adults. It is the only topical minocycline product approved for this indication. The same manufacturer markets minocycline foam 4% (Amzeeq) for treatment of acne in patients ≥9 years old.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):179-80 | Show Introduction Hide Introduction

Semaglutide (Ozempic) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
-weekly subcutaneous injection of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo ...
In recently published clinical trials, once-weekly subcutaneous injection of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, has reduced body weight significantly in patients with and without type 2 diabetes when given in addition to lifestyle intervention. Liraglutide (Saxenda), another GLP-1 receptor agonist, has been FDA-approved for chronic weight management...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):53-4 | Show Introduction Hide Introduction

Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1 ...
The FDA has approved the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that highly expresses programmed death-ligand 1 (PD-L1) and has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations. About 25% of patients with advanced NSCLC have tumors with high levels of PD-L1 expression (PD-L1 expressed on ≥50% of tumor cells). Pembrolizumab was approved earlier for treatment of metastatic NSCLC...
Med Lett Drugs Ther. 2017 Jan 30;59(1513):22-3 | Show Introduction Hide Introduction

Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019  (Issue 1577)
Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations ...
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and...
Med Lett Drugs Ther. 2019 Jul 29;61(1577):120 | Show Introduction Hide Introduction

An EUA for Bamlanivimab and Etesevimab for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
/or hospitalization (see Table 1).1 Bamlanivimab received an EUA for use as monotherapy in such patients in November ...
The FDA has issued an Emergency Use Authorization (EUA) for Lilly's investigational monoclonal antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) to be administered together for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease and/or hospitalization (see Table 1). Bamlanivimab received an EUA for use as monotherapy in such patients in November 2020. Regeneron's investigational monoclonal antibodies casirivimab (REGN10933) and imdevimab (REGN10987) are also authorized for use together for the...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):49-50 | Show Introduction Hide Introduction

In Brief: New Recommendations for Gonococcal Infection

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
for patients with uncomplicated urogenital, rectal, or pharyngeal gonorrhea.1 RATIONALE — Previous CDC ...
The CDC has issued new recommendations for treatment of gonococcal infection. A single 500-mg IM dose (1000 mg in patients weighing ≥150 kg) of the third-generation cephalosporin ceftriaxone is now the treatment of choice for patients with uncomplicated urogenital, rectal, or pharyngeal gonorrhea.
Med Lett Drugs Ther. 2021 May 3;63(1623):72 | Show Introduction Hide Introduction

Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms 1. KJ Ivey. Anticholinergics: do they work ...
The FDA has approved adjunctive treatment with Dartisla ODT (Edenbridge), a new orally disintegrating tablet (ODT) formulation of the anticholinergic drug glycopyrrolate, to reduce symptoms of a peptic ulcer. Glycopyrrolate oral tablets (Robinul, Robinul Forte, and generics) were approved for the same indication in 1961.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):24 | Show Introduction Hide Introduction